Investigating the effects of SGLT inhibitors on liver disease in cystic fibrosis rabbits
Targeting SGLTs for liver disease in a rabbit model of cystic fibrosis
This study is looking at ways to help improve liver health for people with cystic fibrosis by testing a new treatment in rabbits that could break the cycle of inflammation and other problems caused by cystic fibrosis-related liver disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11089442 on NIH RePORTER |
What this research studies
This research focuses on cystic fibrosis-related liver disease (CFLD), which is a significant health issue for patients with cystic fibrosis. The study utilizes a rabbit model that mimics the liver disease symptoms seen in cystic fibrosis patients. By testing sodium-dependent glucose cotransporter (SGLT) inhibitors, the researchers aim to disrupt a harmful cycle of inflammation and metabolic disorders that contribute to CFLD. The goal is to identify potential therapeutic strategies that could improve liver health in cystic fibrosis patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis who are experiencing liver-related complications.
Not a fit: Patients without cystic fibrosis or those who do not have liver disease related to cystic fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve liver function and overall health for cystic fibrosis patients.
How similar studies have performed: Previous research has shown promising results with SGLT inhibitors in other contexts, but this specific application in cystic fibrosis-related liver disease is novel.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Xu, Jie — University of Michigan at Ann Arbor
- Study coordinator: Xu, Jie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.